

Nectar Lifesciences Ltd.



Ref.: NLL/CS/2025- WFH

July 08, 2025

To

1. National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051
Symbol: NECLIFE

2. BSE Limited
Corporate Relationship Department,
P J Towers, Dalal Street,
Mumbai 400 001
Scrip Code: 532649

Sub: Press Release – Nectar Lifesciences Announces Strategic Sale of API and Formulations Business to Ceph Lifesciences for ₹1,270 Crores

Dear Sir/ Madam,

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Press Release issued by the Company on the captioned subject, the content of which is self-explanatory.

This is for your information and record please.

Thanking you,

Yours faithfully,
For **Nectar Lifesciences Limited**

(Sanjaymohan Singh Rawat)
Company Secretary & Compliance Officer

Nectar Lifesciences Announces Strategic Sale of API and Formulations Business to Ceph Lifesciences for ₹1,270 Crores

Chandigarh, July 8, 2025 – Nectar Lifesciences Limited (NSE: NECLIFE, BSE: 532649), a leading pharmaceutical company, today announced the signing of a definitive Business Transfer Agreement (BTA) for the sale of its core business division—comprising the manufacture, distribution, and marketing of active pharmaceutical ingredients (APIs) and formulations—to Ceph Lifesciences Private Limited, for a consideration of ₹1,270 crore (INR 12,70,00,00,000), on a slump sale basis.

Additionally, the Company has entered into an Asset Purchase Agreement (APA) for the sale of its menthol business assets to Ceph Lifesciences for ₹20 crore, marking a comprehensive restructuring move aligned with its future strategy.

Strategic Purpose and Value Creation

This transaction forms a part of Nectar Lifesciences’ long-term strategy to streamline its operations, strengthen its financial position, and unlock value for shareholders. The proceeds from the sale will be used to:

- Repay existing debt
- Invest in new and emerging business areas
- Reward shareholders, subject to applicable approvals
- Fund future corporate and growth initiatives

Chairman’s Statement

Mr. Sanjiv Goyal, Promoter and Chairman of Nectar Lifesciences, commented:

“This transaction marks a significant milestone in Nectar Lifesciences’ evolution. By divesting mature segments of our business, we are laying the foundation for a focused and agile organization geared towards innovation and long-term value creation. We thank our stakeholders for their continued trust and support as we embark on this next chapter.”

Transaction Overview

- Buyer: Ceph Lifesciences Private Limited (a third-party, non-promoter entity)
- Consideration: ₹1,270 crore for the core API and formulations business; ₹20 crore for menthol business assets
- Completion: Expected on or before September 20, 2025, subject to customary approvals

- Shareholding Pattern: No change in the Company's existing shareholding

The transaction was approved by the Company's Board on July 7, 2025, and is subject to shareholder approval at the Extraordinary General Meeting (EGM) to be held on August 4, 2025.

About Nectar Lifesciences Limited

Nectar Lifesciences Ltd. is an established pharmaceutical company focused on research-driven innovation, manufacturing, and global distribution. The Company is listed on the NSE and BSE and is committed to enhancing stakeholder value through disciplined strategy and operational excellence.

